CMS authorizes no-cost monoclonal antibody treatments for Medicare beneficiaries

Nov 11, 2020 - 03:21 PM
CMS logo

The Centers for Medicare & Medicaid Services yesterday announced Medicare coverage for monoclonal antibody therapies, with no beneficiary cost-sharing for the duration of the COVID-19 public health emergency. CMS said the coverage will apply to bamlanivimab, the Lilly therapeutic that earned an emergency use authorization earlier this week. Additionally, the agency said it anticipates that bamlanivimab and other, similar therapies will initially be given by drug makers to health care providers at no charge; as such, the Medicare program will not pay for monoclonal antibody products that providers receive for free.

Medicare will, however, reimburse for these therapies’ infusion. Once health care providers begin purchasing monoclonal antibody products, CMS anticipates setting the payment rate in the same manner it uses to set COVID-19 vaccine payments. Additional details for providers about Medicare coding, payment and billing for monoclonal COVID-19 products and their administration are described in CMS’ Medicare Monoclonal Antibody COVID-19 Infusion Program Instruction.

Related News Articles

Headline
FDA issues serious recall for electric wheelchair joysticks
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
AHA supports bill expanding in-network providers within MA plans 
The AHA Sept. 15 expressed support for the Ensuring Access to Essential Providers Act, legislation that would require Medicare Advantage plans to cover…
Headline
AHA urges Aetna to rescind ‘level of severity inpatient payment’ policy
The AHA Sept. 15 urged Aetna to rescind its recently announced “level of severity inpatient payment” policy, saying that it “could erode the transparency…
Perspective
Hospital Outpatient Departments Are Different from Independent Physician Offices
Public
Every health care provider strives to deliver their patients the best possible care, but not all providers offer the same level or complexity of care. Current…
Headline
Study: MA beneficiaries’ hospital stays longer than those under Traditional Medicare
A JAMA internal medicine study published Sept. 8 found that since the COVID-19 pandemic, Medicare Advantage beneficiaries have been experiencing longer…
Headline
Study finds less than 40% of Medicare beneficiaries with OUD receive standard care
A Health Affairs study published Sept. 2 found that less than 40% of Medicare beneficiaries with opioid use disorder received standard care in alignment with…